Health Care Professionals’ Perspectives are Essential to Greater Biosimilar Adoption

Monday August 15, 2022

Since the first biosimilar was approved in the U.S. in 2015, these life savings therapies have provided nearly $13 billion in savings to patients and the health care system. In addition to bringing down the price of expensive biologic therapies, biosimilars have increased access to care, with biosimilars used in over 121 million days of patient therapy and nearly 10 million days of patient therapy that would otherwise not have been provided.

Despite this progress, barriers to patient access to biosimilars persist. For example, some brand companies use misinformation and disparagement campaigns to sow doubt about biosimilars among both physicians and their patients. To combat these efforts, the Biosimilars Patient Resource Center provides information, like Frequently Asked Questions and helpful links to resources from the U.S. Food and Drug Administration and other groups.

This website also provides a place for medical professionals and patients to share their stories. For example, Dr. Sameer Awsare, Associate Executive Director, The Permanente Medical Group gave his perspective on biosimilars’ safety and efficacy,

“…it is absolutely safe for a patient to switch from a biologic to a biosimilar because their qualities are similar. They actually work for the same kind of condition and their purity is the same and they’ve actually been tested for the same kinds of conditions. We have studies from all over they world and we find that patients have the same kind of benefits whether they are on the original biologic or the biosimilar.”

Showcasing trusted medical professionals’ experience is an effective way to combat misinformation and provide a relatable explanation about biosimilars in a way that the underlying data points and study results cannot. We encourage health care professions to visit the Patient Resource Center and share your story to create awareness about the positive impact biosimilars have on patients.

We also have additional resources on biosimilars and information about how you can join the biosimilars movement and advocate for greater access on our advocacy page.

Share Your Voice

Click the button below and tell us about your experiences with biosimilars.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.